Page 1,248«..1020..1,2471,2481,2491,250..1,2601,270..»

Seeking the Killer Space App with Space Tango – The Planetary Society

Posted: December 3, 2019 at 1:43 pm

Organizations are using the microgravity environment of the International Space Station to develop unique new products. One of them is Kentucky-based Space Tango. Well meet its chairman and co-founder and the woman who manages its Tangolab. Also, a NASA rep who works with these pioneers. Time magazine has named the Planetary Societys LightSail its aerospace invention of the year! Society CEO Bill Nye is grateful to all who have been part of the project. Bruce Betts provides a solar sail update at the top of this weeks Whats Up, and wishes Mat a happy 17th anniversary of Planetary Radio.

What is the largest known object in our solar system that, as of now, has NOT been visited by a spacecraft? Flybys count. The Sun does not.

What is the new or relatively new name for the most distant object visited by a spacecraft?

The winner will be revealed next week.

The Mars Science Laboratory Curiosity was the first spacecraft to see a planetary transit (Mercury) from another planet.

Mat Kaplan: [00:00:00] Hemp in space, how about beer? That's this Week on Planetary Radio.

Welcome. I'm at Kaplan of the Planetary Society with more of the human adventure across our solar system and beyond. Kentucky based Space Tango is actually conducting International Space Station research on far more than the catchy items in my opening line. We'll talk with co-founder Kris Kimel and others about the burgeoning effort to find the killer app or product for production at Zero-G. Happy Anniversary to us whose stats will help me celebrate 17 years of Planetary Radio in this week's what's up. He'll also give us a LightSail 2 update.

LightSail is also why we'll be joined by Planetary Society CEO, Bill Nye the planetary guy right after we check in with the downlink. The Planetary Society's weekly collection of the top headlines in Space [00:01:00] exploration presented by our editorial director Jason Davis. The insight lander on Mars keeps plugging or pounding away with help from the crafts robotic arm. The long trouble Mole hit probe is once again hammering itself below the surface of the Red Planet. Boeing has put at CST 100 Starliner spacecraft on top of an atlas five rocket. With luck, it will make its first voyage to the ISS in December. Science human crew, I'll also note that SpaceX hopes to fly a test of the Crew Dragon capsules escape system next month. Meanwhile, a prototype of that company Starship blew its top a few days ago. SpaceX says the mishap shouldn't delay development of the huge vehicle.

Lastly, scientists have for the first time directly detected water vapor above Europa using the Keck Observatory in Hawaii. The finding support prior research indicating that there may be transient [00:02:00] plumes erupting from the moon's subsurface ocean. Though other explanations are also possible. Go Europa Clipper. For more on these and other stories, including great links, visit planetary.org/downlink. Now to Bill Nye, who is celebrating recognition of the Planetary Society's LightSail solar sail project by the leading news magazine in the US. Bill, not that we needed Time Magazine to acknowledge the, uh... our pride or the success of LightSail 2 but, but it doesn't hurt, does it?

Bill Nye: No, no, it's pretty cool. So Time Magazine's inventions of the year, we are the aerospace invention of the year. It's certainly a heck of a thing. You know, and it's of the year, of, of a year. This thing depend when you start counting is you know, 42 years in the making. And so, uh, it's really gratifying, you know. And for those members who are listening or people who are not yet members, you know, [00:03:00] we flew Cosmos 1 in 2005 but it ended up in the ocean. And then we had an opportunity, uh, four years ago to fly LightSail 1 and we just took it because you just don't know when you're gonna get an opportunity to, to get on a NASA Flight or an ELaNa, Educational Launch of Nanosatellites opportunity so we took that. But LightSail 2 we were able to get to a high enough altitude, 720 kilometers where we could prove that the thing works. Is just... It's really gratifying, Mat. It's just cool as heck.

Mat Kaplan: You mentioned our members, but other people as well. I hear the number 50,000 bandied about.

Bill Nye: Yeah. That's what we say. 50,000 people contributed to LightSail... the LightSail program. Most of them were more recent LightSail 2 when we had Kickstarter awareness and so on. So, thank you all. Really, Mat, another extraordinary aspect of it is, I mentioned Kickstarter, that was one way we raise money, but the main way is just through membership in the Planetary Society. We did [00:04:00] our first $7 million over, over, uh, it depends how you count, over the last 12 years or what have you. If you were gonna do that at a regular space agency like NASA, or ISA, or CNES, or French Space Agency, it would cost about, people estimate about 20 times as much. 140, 150 million to do this project to fly two Solar sails in Earth orbit.

And the reason we did it so much more cheaply is we took risks. And we also do not have continuous coverage around the world. We don't have the Deep Space Network, we just have Hawaii, San Luis Obispo, California, Purdue in Indiana and Georgia Tech in Georgia in the US. And so it's very cool. We pulled it off.

Mat Kaplan: And I am very proud. I am, I'm proud to be a member who stood behind this, who stands behind this and I... I'm proud to be part of the organization, if not a direct part of the team that, uh, that put it up [00:05:00] there.

Bill Nye: Yeah. I'm not a direct part of the team either, Mat, I'm, once in a while I'd say, "Okay, write a check."

Mat Kaplan: [laughs]

Bill Nye: No. So the, the problems that these guys and gals overcame is really, really exciting. You know, and, and pers... the whole thing is so romantic, you know. If you're keeping track, it goes back to Johannes Kepler in 1607 looking at what we now call Comet Halley... Halley's Comet before Edmond Halley ever saw it. He noticed this comet in the night sky, and he noticed that the tail, noticed very carefully that the tail always pointed away from the sun. And Kepler, not really having any knowledge of photons or modern physics of light, he just reason that there's something about the sun that's creating this tail or these tails, the ion tail and the dust tail. Then 400 years later, we were able to exploit that feature of sunlight to fly. It's just exciting.

And so we [00:06:00] hope, as, as the goal of the Planetary Society this... democratizes spaceflight that other organizations, universities will use Solar sails to go to other destinations in the solar system.

Mat Kaplan: Or perhaps beyond.

Bill Nye: Whoo. Yeah, it really is the only technology anybody's thought of right now that could take you to another star system and that is you build a Solar sail, uh, similar in shape to LightSail 2 and you give it a push with a la- with a laser or a group of lasers either on earth or on the far side of the moon, has been discussed, where you'd have solar panels to make electricity to crank huge lasers and give this thing a push. And so the existing drawings, or plans, or artists concepts of inter [inaudible 00:06:48] or flight, uh, always... we always have a square sail very similar to LightSail. You know, you converge on the same answer, right? Do you want booms, things to hold the sail rigid, [00:07:00] or would you rely on just the spin of a sail. Just the centripetal centrifugal action of, uh, something on the, on the corners or the ci- circumference of the sail... perimeter of the sail. And, uh, now right now everybody's thinking is we... booms are good. Booms ar, are efficient.

Mat Kaplan: I would say that LightSail has had a good part in helping to convince people that those booms are a, are a, a, a good way to go.

Bill Nye: Or a worthy way to go. So everybody if you haven't done it, go to our control panel-

Mat Kaplan: Mm-hmm [affirmative]-

Bill Nye: Our mission, mission control, rather, on our website, planetary.org, and you'll find when you can go looking for it in the night sky, in the evening sky, the morning sky. It's really something... when... it's just a dot, it's just a pinprick of light, but it's, it's our.of light people built by citizens around the world who just thought that this was a worthy technology to pursue, and this... there are a couple missions [00:08:00] that a future LightSail style spacecraft is ideal for climate monitoring from above the poles, and, uh, the search for asteroids and especially monitoring solar weather. So there'll be a coronal mass ejection event on the sun. And this stream of particles is hurtling toward our planet that would damage... excessively damage, will create excessive damage to our satellites, to our space assets.

And with the solar sail station keeping with the earth at an inferior orbit, say around the orbit of Venus 0.7 astronomical units from the sun, you could get a head start. You could get three, three and a half, four hours warning against the stream of charged particles. In 2012 there's a very serious event that mised the earth by about two weeks.

Mat Kaplan: Mm-hmm [affirmative]-

Bill Nye: It, it slashed through Earth's orbit two weeks behind us. So we, uh, we... this is a real practical use of this technology along with the [00:09:00] romance.

Mat Kaplan: And I will say with a wink of my eye as we close here, more news approaching, more honors approaching-

Bill Nye: Oh, yes. Yes, your eyes are, are a wink.

Mat Kaplan: [laughs]

Bill Nye: That's cool. It's... But you guys in Time Magazine, come on, it's like Person of the Year, except it's our spacecraft with 99 other cool inventions. Carry on, Mat.

Mat Kaplan: Thank you, Bill. We will. Thanks for, uh-

Bill Nye: Let's keep them flying.

Mat Kaplan: Thanks for the leadership. That's Bill Nye. He's the CEO of the Planetary Society, which, uh, stands behind and under LightSail 2, which, uh, could be sailing on the light of the sun over your head right now.

Another SpaceX Dragon cargo capsule will head for the International Space Station in early December. It will carry a metric ton of science experiments to that national laboratory. One of them will contain barley seeds provided by none other than Anheuser-Busch Brewer of Budweiser and [00:10:00] many other beers. The fascinating story behind this and other efforts is what brought me in early October to the Kentucky headquarters of Space Tango. My host was the company's co-founder and chairman, Kris Kimel. Kris, it's pretty fun to be here at the home of Space Tango in, uh, Lexington, Kentucky. What is happening here? I see a whole bunch of workbenches.

Kris Kimel: Well, fundamentally there's... everybody's preparing for the next launch. Space Tango, of course, is really a research design and manufacturing company that just doesn't do work on the planet Earth. Uh, so everybody is busy preparing for, uh, a series of missions and experiments that will go up on, on the next launch, which I believe is going to be in, in late October. Um, we'll... we generally launch now about, about, uh, six times a year. So it's always very active. Uh, a lot of interesting things going on, and what you're basically around is all the, uh, engineering capabilities as well as some of the biotechnology.

Mat Kaplan: You know, the line from, uh, Captain James Kirk. He said, "Yeah, I'm from Iowa. I just work up there."

Kris Kimel: That's [00:11:00] basically it. Yeah. You know, I tell people about... when I give talks often, I say that or if I'm talking about some of the biot... biomedical things that we do that are really interesting. I sometimes say, you know, "What if the next big... Have you ever thought about it, the next big biomedical breakthrough isn't on the planet Earth?" Just to give them a sense of, yeah, its space it's exotic. But on the other hand, it's really just a... it's another physics environment. And we along with others are now be a- able to exploit that physics environment, use that physics environment for trying to answer different kinds of questions and look for different kinds of solutions.

Mat Kaplan: You're the chair... chairman, but you're also one of the co-founders. Why did you wanna create a company like this?

Kris Kimel: I would like to say that, oh, um, it all started when I was five years old, um, but it didn't have... I think a lot of people my, my, uh, my interest in my career have been very circuitous. Um, at one point I was president of the Kentucky Science Technology Corporation. Um, and that's where the genesis for this, this kind of organization started to, to percolate and we [00:12:00] created... the first organization we created was something called Kentucky Space, which was an independent nonprofit subsidiary. And, um, actually we started thinking we were going to, to build, um, small satellites. CubeSat.

Mat Kaplan: Mm-hmm [affirmative]-

Kris Kimel: Is which was where we started. We started will help high-altitude balloons, then moved to suborbital and into orbital. Um, actually Twyman Clements, who's now the CEO of Space Tango was actually hired, hired as a student to work at Kentucky space. So he's, he's been there since the... he's the other co-founder and has been there since the beginning. It kind of evolved.

And as we started to go into the, the CubeSat, uh, arena, and then had, had an opportunity to build something for Space Station, it was just one of those things where I think our curiosity, um, and the opportunity kind of converged and then we realized that low Earth orbit and microgravity, uh, may be a, a revolutionary, uh, new pathway for all sorts of no... new discoveries with materials and, and particularly in the, in the biomedical area for applications on earth in addition to no space medicine, which is, you [00:13:00] know, how do we keep people alive in space? Which is obviously a, a big issue too. But really our focus has been more on how do we, you know, utilize microgravity for... to benefit people on earth.

Mat Kaplan: Kentucky Bourbon Thoroughbred's, nothing against this town. It's a lovely town. But Lexington, Kentucky is not the first place most people think of in terms of developing or exploring space. And yet you've been able to build this company here. I mean, it seems to say something about the progress that we've made in space development, space utilization.

Kris Kimel: Well, I think clearly over the, particularly the past 10 years, five to 10 years, the spa- you know, the space industry, commercial space research has, has really opened up. I think a couple things have been driving that that made it more difficult for places like Lexington or people here and other places to get involved. One was the access to space. Um, I, I think since actually I think, at the time, it was controversial, but I think NASA's decision to scrub The Shuttle, uh, and then move to a different vehicle and encourage the private [00:14:00] sector to get involved, really opened things up. Uh, it was very difficult for anyone to compete with The Shuttle because of the cost and et cetera. I think that opened things up.

The other thing I think it's really been... is revolutionary, uh, is just the relentless and continued, uh, miniaturization and develop of new technologies.

Mat Kaplan: Mm-hmm [affirmative]-

Kris Kimel: Everything that we do here most everything is, um, is very small, very robust, very technical, and that ability to develop very, very small technologies, uh, and be able to partner with a NASA, or an Orbital, or SpaceX or some of the other vehicle, uh, launch vehicle companies to put things it's ve... it's really something that was not available 10 years ago. And because of that, I mean, we have a lot of people here in Lexington, like everywhere else in the country in the world that have great ideas and are very smart. I think a lot of things that, that may be kept us from creating, uh, synergy here in the past wasn't the lack of ideas. It wasn't a lack of people. It was just lack of the infrastructure and ability to do that.

Um, you know, you needed big stuff, you needed to be, you know, [00:15:00] you needed to, to handle... to launch capability or be near a NASA facility. And I think that's all changed. And that's opened a lot of opportunity up for places like this.

Mat Kaplan: What is the infrastructure? I mean, what have all these developments allowed you to create on the International Space Station so that you can basically host this work?

Kris Kimel: Uh, I think it's a lot of things. Uh, our, our engineers probably have or have a better deeper sense of some of the specifics. But clearly, we now know... we know, um, that, you know, when you move into microgravity, all biological and physical systems are scrambled. Uh, and that scrambling process, uh, opens up a whole new, uh, opportunity, one, to understand, uh, how things operate not only in microgravity, but they act differently there. Is it, you know, sometimes it tells us something about the system, how it operates on earth that we may not have seen on Earth. Just very briefly, we did an experiment a year, a year or two ago with Tuft University dealing with planarian flatworm is which our major focus were regenerative medicine. Those of you who didn't sleep [00:16:00] through high school sciences, I did.

Mat Kaplan: [laughs]

Kris Kimel: Know that when you cut them in threes, they regenerate heads, tails, and the midsection grows a head and tail. So they were very interested in one big, you know, focuses. Understand that mechanism. So we put, you know, we put 15 in space and then cut 15 other and cut them. And when we came back, they saw some really interesting differences. And one of the most intrig- intriguing differences they saw is that one of the mid sections had grown to heads. And I believe their offspring had two heads. So that's one of those things where you go, "Gosh, wh- wh... how did that happen?" And we don't know.

A lot of times people will ask us when we're doing experiments, "What do you think you're gonna see when you send something..." we planned experiments, for example, uh, plants that are the basis for chemo drugs, looking for chemistry changes or any kind of alterations. We've done, you know, things with stem cells, brain organoids. And people often ask, "What do you think you're gonna see?" And the answer most of the time is, "We don't know." Uh, this is very much a frontier and that's why we're going to space. But that microgravity environment, because of its very nature is, is opening up and allowing us and [00:17:00] others into a different room to look for different kinds of solutions that really we haven't been able to do in the past.

Mat Kaplan: Of course, that brain organoid work, we're also talking about because of the folks at UCSD that you're working with. But I'm curious about some of the other... some of these other experiments that have been set up. Uh, what's this thing about hemp?

Kris Kimel: Well, uh, we're a curious company. People understand that one of the aspects of, of Space Tango is that we, we don't see ourselves simply as a service company or a transactional company. I mean, that's a lot of what we do right now. Uh, but we also see ourselves as an idea company. We see ourselves as a company also pushing the envelope with our own ideas or ideas in partnership with others, to try to figure out new ways and new things, new ideas. We became, uh, very interested last year in looking at some of the potential biomedical applications primarily of things like cannabinoids, and CBD, and, and things of that nature and did a lot of research on, on CBD and of course, hemp being the non psychoactive cousin of THC, [00:18:00] and discovered, discovered or you know, uncovered in our mind, some... we thought are some very interesting opportunities to look at the properties of cannabinoids in a Zero-G environment.

Um, for example there's over, I think approximately 130 cannabinoids actually. And we really could only access wi- with any degree of accuracy and volume, a co... just a couple [inaudible 00:18:22] a THC and CBD I think, CBA or CB other things, other... a few others. But... So, one of the things we're really interested in is do we see which we have seen in the past with other planets perhaps epigenetic changes in the space that might turn on some of those genes that might, uh, allow us to see or turn on or activate, uh, other kinds of, of, uh, cannabinoids, uh, et cetera. Do we see differences in the plants and the chemistry and the genes. And so our really interest is looking at cannabinoids, looking at the hemp plant in that environment as a possible, understand is a possible pathway to enhancing the biomedical potential.

Mat Kaplan: Mm-hmm [affirmative]-

Kris Kimel: [00:19:00] Uh, and health and, and wellness potential of CBD and other cannabinoids and other chemistry that are part of the hemp plant.

Mat Kaplan: So it's 95 degrees here today in Lexington, I maybe therefore I'm not that sorry that we're not gonna make it out to a field just out of town. You showed me some pictures and maybe we'll post one of those on the show page. Uh, were you doing a little bit of cultivation.

Kris Kimel: Yeah. Um, Space Tango is a small company, uh, which is great. And when you're in a small company, uh, you have to do a lot of things. And, uh, when we brought the hemp seeds back one of the things we did we planted them in a greenhouse, uh, and then we grew them out of the greenhouse and evaluated them, uh, at certain, certain intervals. And then we're gonna put them in the field and then once they've grown out in the field, and then harvest them from the field at a particular, uh, interval and then do genetic and chemistry analysis and see what, what, uh, might evolve from that point.

And, um, as luck would have it, last week, I got a call on Tuesday from one of our... Rob Gabbert who works with us and said, "Hey, we got to get 60 plants out in the [00:20:00] field by Friday." And I said, "Well, Who's we?" And he said, "Well, I guess it's you and me since the engineers are busy preparing for the next flight and we don't have, you know, people out there."

So, um, I put on my, my, my jeans and work shirt and Rob and I went out and dug and planted, uh, 60 holes and planted out, uh, 60, uh, of the hemp plants that had been in the, in the greenhouse that he had both the control group and the plants that had been, uh, the dry from seed that had been in space. Uh, and I will say, like a lot of places in this country, it hasn't rained here in about two months. So the, the ground was rock hard.

Mat Kaplan: Mm-hmm [affirmative]-

Kris Kimel: Uh, but that's what we had to do. And that's like a small company. You do what you have to do. There's no such thing as a small company as, that's not a good use of my time.

Mat Kaplan: Such other duties as maybe a sign.

Kris Kimel: That's right.

Mat Kaplan: I- I'm curious about the relationship with NASA. Because obviously, the space agency had to enable these things to happen on the ISS. How does that work for you?

Kris Kimel: NASA has been an, an amazing partner with Kentucky Space and Space Tango from the very beginning, as they have with a lot of other emerging space companies. We fortunately have [00:21:00] something called a Space Act Agreement with NASA that basically, uh, gives us access to the station, it gives us launch opportunities in partnership with NASA and some of the launch, launch companies. And so they're very much, uh, very much a... an ongoing full time really partner o- of what we do. Um, and wi- without NASA and some of their new innovative policies, we certainly couldn't... wouldn't able to be achieving what we do. And, uh, those Space Act Agreements and other kinds of, of collaborations that we have in NASA are, are absolutely essential. Not only to I think Space Tango, uh, feature, but really the, the, the commercialization of space in general.

Mat Kaplan: It sure seems like all of this is still happening at a pretty embryonic level. Do you see enormous potential? Do you expect to see, well, I'll call it the killer app, but it might be a killer product or do you think that microgravity is going to pay off basically? Not just in terms of a profit for you and your partners, but in, in terms of, uh, helping us down here on the surface of [00:22:00] earth.

Kris Kimel: Absolutely. Um, a lot of times its Space Tango we talk about. You know, every time we've, we have been able to get a hold of, or, uh, capture a physics environment, a new physics environment, um, harness it, whether it be, uh, electromagnetism or the vacuum, it has led to a couple of things. It has inevitably led to exponential growth in new ideas and, and applications and, and significant capital creation. And really what we're talking about here is the fact that we are now at the beginning of being able to harness the physical environment of microgravity in a real way.

You know, on Earth, you can't mimic it on Earth, you know, drop towers, you know, the vomit comet, you get a few minutes, but-

Mat Kaplan: Mm-hmm [affirmative]-

Kris Kimel: ... you really don't get any kind of prolonged exposure like we do now. And yes, we're on the, we're on the cusp of that. But just like other physics environments, we fully expect and anticipate that this too, uh, we will look back upon, um, in the years ahead and realize that this was a, a monumental breakthrough that has led to all [00:23:00] sorts of new understandings and improvement in, in people's lives.

Mat Kaplan: We like pioneers on this show. Kris. Thank you. Exciting stuff. Best of success.

Kris Kimel: Thank you.

Mat Kaplan: That's Kris Kimmel. By the way, we'll learn more about those so called brain organoids Kris mentioned in an upcoming episode of Planetary Radio, stick around, we're about to meet the woman who manages all of the amazing research taken on by Space Tango and its clients.

Casey Dreier: I know you're a fan of space because you're listening to Planetary Radio right now. But if you want to take that extra step to be not just a fan, but an advocate, I hope you'll join me Casey Dreier, the Chief Advocate here at the Planetary Society at our annual Day of Action this February 9th and 10th in Washington, DC. That's when members from across the country come to DC and meet with members of Congress face to face and advocate for space. To learn more, go to planetary.org/dayofaction.

Mat Kaplan: Back to Space Tango.

Gentry Barnett: My name is Gentry Barnett and [00:24:00] I am the TangoLab Program Manager at Space Tango.

Mat Kaplan: And do a lot of the biomedical stuff here right here.

Gentry Barnett: I am a biomedical, uh, engineer by trade. Yes. And so I, I, I oversee all the payloads in this role. For each mission we'll select a couple of mi... payloads for that mission depending on payload readiness, uh, and some of the logistics they need for each flight. So that, that kind of determines what payloads go on a mission. Uh, yes, and then I will oversee all those, the development, the engineering, uh, a- and making sure those get to space.

Mat Kaplan: So as our listeners know, I'm a gear head at least that's what my boss, the, the science guy says. Uh, this is kind of heavenly. And tell me about this amazing collection of circuit boards, and tubes, and, and a bag of seeds. What's going on here?

Gentry Barnett: So this is actually a payload that's going up on our next mission. This is a payload with, uh, Anheuser-Busch. Um, what they're looking at or the seeds you're looking a, um, are barley seeds.

Mat Kaplan: Uh-huh.

Gentry Barnett: And, and they're really exploring with this payload, the malting process. [00:25:00] Uh, wh- which consists of three different phases: Steeping, uh, germination, and kilning. Normally, obviously, they do this in a much larger environment. Um-

Mat Kaplan: They make a lot of beer.

Gentry Barnett: Yes, they do. Uh, so we, we went out to their facilities in Fort Collins, Colorado, uh, to learn this process. So what we do, uh, uh, air space thing, uh, with the engineers is, is we really miniaturize that process, uh, into something, um, slightly bigger than a, than a shoe box, uh, which we call a CubeLab. Uh, and this is a self-contained environment, uh, that we automate from our offices in Lexington.

Mat Kaplan: They come to you Anheuser-Busch, "We would like to do something about malting, part of the beer mak... process of making beer in space in microgravity. You figure out how to make that work on the ISS.

Gentry Barnett: Yes, that's exactly what we do. A- as an engineer i- in this, uh, specific company, we have to have a very quick, uh, learning process. So, yes, we went out there, we, we went over the process that they normally [00:26:00] do. Uh, a- and then we have to, we have to miniaturize that. We have to learn each component of that. Uh, a- and then we'll set up what, what you're seeing in front of you, uh, this is the payload sprawled out, uh, i- in more of a benchtop prototype fashion, uh, so that we can see every functional piece of how this is working and, and follow along at e- at every step of the way.

Um, and what you'll see in the bag over here is actually the, the end of the steeping process. The seeds have actually developed these acro spires which is tunney, uh, growth at the end o- of one end of the seed. Uh, and that's exactly what we were looking for. So then tomorrow we'll, we'll go into the germination phase. Uh, and then the kilning where we will actually draw these seeds out and the end result will be malt that will send to them and they'll do a chemical profile and compare that... the different chemical profile and the, the taste profile, uh, that results from this malt. Uh, and then obviously we'll do the same thing for the result and malt that comes back from the Space Station.

Mat Kaplan: So this will all go into, I assume some kind of a rack mount unit and the self contained? I mean, [00:27:00] will astronauts have to tend this or will it pretty much take care of itself.

Gentry Barnett: Uh, no, once we, once we, uh, put the tops on our CubeLabs they become a, a self contained environment. So really the only crew interaction that we have is moving it from the rocket that takes it up. So either from the dragon or the Cygnus module, uh, will take that out and install it into our TangoLab facilities, um, on the Space Station that are in EXPRESS rack. And from that point forward, they will be fully automated. And we control that from our up station, um, here in Lexington upstairs.

Mat Kaplan: Is this experiment that has already been completed at least the first phase of it with so called brain organoids that we're also talking about today. Is it essentially similar to this? Where they, they came to you from UCSD and you had to figure out how to make it go into space?

Gentry Barnett: Yes, absolutely. So with the UCSD project, the brain, the organoids, they're studying how the brain develops, uh, in a microgravity environment under these different kinds of stresses that are normally [00:28:00] seen on Earth, obviously. What we have to do, um, as Space Tango is we have to take the environment that they have, uh, in their labs at UCSD, you know, how they normally keep these cells alive and do that in a much smaller, automated, fully sealed environment. Um, so we, we work directly, uh, you know, one on one with that team to understand their different requirements, uh, to explain our different requirements and really come together to develop this very unique, uh, minilab system that's put in our CubeLab.

Mat Kaplan: From beer to brains, with all kinds of other stuff in between, seems like a pretty fun job.

Gentry Barnett: Absolutely. It is a lot of fun. What's unique about everybody that works here and really all of our customers, um, is we're willing to discover. And we're willing to open the doors to whatever we may find, whatever we may not find. Uh, we're, we're always looking for another answer. We're always asking a different question. That drive for innovation, the drive for something new, just asking the question of, of what could happen, [00:29:00] uh, that's really what makes this job so interesting, and I think what brings a lot of our customers to our doors.

Mat Kaplan: Have you seen enough that you have confidence as Kris Kimel does in the potential of microgravity for developing manufacturing products that will be unlike any we can create on earth?

Gentry Barnett: 100%, yes. There's, there's really endless potential here. Uh, and again, it's just being... having that willingness to ask these questions. Every question you ask may not have this profound answer that you were expecting, uh, that these unique, I guess, side questions that you could also ask along the way, tend to bring results that you weren't expecting.

Mat Kaplan: Mm-hmm [affirmative]-

Continue reading here:
Seeking the Killer Space App with Space Tango - The Planetary Society

Posted in Indiana Stem Cells | Comments Off on Seeking the Killer Space App with Space Tango – The Planetary Society

Thuppakki to Petta: Tamil cinemas 15 best masala movies of the decade – The Hindu

Posted: December 2, 2019 at 9:48 am

(A word of caution: You like chai, I like kaapi. You like Nadhiya, I like Amala. This list is as simple as that. Do not tell me I didnt warn you.)

If there is something we, as humble citizens of India, need to be proud of about our cinema, it has to be the invention of this understated genre called masala. In a recent roundtable discussion hosted by Film Companion, Ranveer Singh made an interesting observation about the lack of appreciation for masala movies the sentiment was concurred by others in the panel. While critics wrote a thesis about his remarkable performances in Padmavat and Gully Boy, he said he was taken less seriously for a movie like Simmba...why? Because it was a masala movie. Now, whether Simmba falls under the masala-movie-done-right category or not is debatable. But you get the point he was trying to make, right?

Masala as a genre is either looked down upon or ignored altogether when it comes to film appreciation. We dont celebrate masala movies with the same fervour of a slightly auteurish filmmaker. But even in the masala universe, there is as much difference between masala and mass as there is between cinema and movies. So, what constitutes a masala movie in the first place? It is simple; it employs archetypical tropes it could be anything from the rise of the underdog template, rags-to-riches story to having mythological subtexts in the most entertaining (this being the keyword) fashion.

Theres a certain level of screenwriting (and by this, I dont mean Prabhas screenplay theory) that goes in writing masala movies, as opposed to say a mass movie, which, basically, offers happy-ending services to a stars fanboys. Trust me when I say this; a well-made masala has the healing power of watching a Kieslowski or a Bergman movie. Tamil cinema, in this decade, has produced an assortment of masala movies, made with genuine vigour and passion. This list is to acknowledge the contribution of auteurs of the other kind.

Hari is one of the rare filmmakers who had been consistently giving us enjoyable masala flicks, until he ran out of fresh ideas. Singam as a standalone movie was so perfect and so tightly-written that you wish it hadnt been turned into a franchise. Right from the casting to writing the cat-and-mouse scenes between Suriya and Prakash Raj (who, by the way, was the spine of Singam), Hari almost got everything right something he couldnt achieve in the preceding movies. Durai Singam as the astute and equally stubborn cop was perfectly tolerable before he was recognised as the loudest cop by the Noise Control Board of India. The number of times this movie has been remade goes on to explain why Singam is a strong contender for the decades best masala movie.

If Mani Ratnam comes from K Balachanders school of filmmaking, Shankar hails from SP Muthuramans. I get what you are thinking. Enthiran? Seriously? The sci-fi tag is just a faade. Look beneath its surface, and you will sense a strong flavour of masala it is what you get when Shankars visual sense meets SP Muthuramans screenplay. Its basically Rajinikanth going against his alter ego, played by...Rajini. The first half is painfully boring and you wish they had given you a red pill instead of blue. The plot kicks in only in the second half, when Chitti gets a new lease of life, thanks to Borah. What Shankar failed to realise when he made the sequel, 2.0, was that Chitti: The Red was the superhero the audience rooted for and not the banal, Chitti: The Blue.

Raghava Lawrence single-handedly created whats now popularly known as horror-comedy, the single most viable sub-genre that will come back to haunt the audience. Nowhere else will you find a wild mix of genres; comedy, action, romance, social message, Kovai Sarala and so on. As much as you hate it, you cant diss the fact that Kanchana was a paradigm shift in the way horror was approached in Tamil cinema. All the movies in the Kanchana series tread a common line: spirits use Raghava Lawrences body as a medium to take revenge, with the (spiritual) presence of Kovai Sarala. If someone had told you that Kanchana would become a multi-million franchise, you might have let out a chuckle or two. But now, the joke is really on you.

Will I not be lynched with hate messages if I dont include Mankatha, the terrific anti-hero movie, which exploited Ajith Kumars solid screen presence to the fullest? A Tamil cinema hero can never be the bad guy this is an unwritten rule in the industry. Even if youre a Velu Naicker, your actions are determined by the number of good deeds you do to the naalu peru. But Venkat Prabhu broke this notion by fleshing out a character that carried devil-may-cry attitude right from the opening sequence. Every frame in Mankatha had a purpose. And the purpose was to capture the star whos both good-looking and carries the I am the one aura around him. Venkat Prabhu constantly toyed with how Vinayak Mahadev (Ajith Kumar) was perceived by the audience. Youd expect the director to make him the good guy in the end, thereby restoring Tamil cinemas fascination for dharma and karma. Thank heavens, Venkat Prabhu gave no room for such notions, and Mankatha was a celebration of the anti-hero.

AR Murugadoss gave a masterclass on how to reinvent an archaic template wherein the hero is pushed into becoming a saviour in what could be argued as THE best masala movie of the decade. In another Vijay movie, he would have been introduced with slow-mo shots exposing just his legs followed by different body parts; hands, eyes and then the face. That happens to a large extent in Thuppakki too. At the same time, it was a rare instance where Vijay was in the character when he makes an entry. The movie is very much about the hero who finds himself at the wrong place and at the wrong time, thereby reducing the villain to nothing more than a buffoon. The scene where Vijay emerges out of a room full of smoke is a textbook example of how to write a mass scene, without compromising on the craft. All of which is to say that I am waiting to watch Vijay go back to his Thuppakki zone. He was an absolute delight to watch the same cannot be said about his recent woke movies.

Kamal Haasan, the writer is more fascinating than Kamal, the actor. Given the political climate, can you imagine a Muslim protagonist saving the world in Indian cinema? Allow me to rephrase it: Can you imagine a vegetarian protagonist-cum-Kathak dancer-cum-RAW Agent saving the world? Kamal has a fetish for mythology and youll always find mythological references/characters in his movies. In Vishwaroopam, he mounts the story of Arjuna when he cross-dressed as a woman in the Mahabharata, on the backdrop of third world politics. Kamal doesnt subscribe to straightforward narration and has great regard for the audiences intellect, even though hes often dismissed for his overt intellectual-ness. As a genre, you could say Vishwaroopam is a spy-thriller. However, the sensibilities are still Kodambakkam. Its essentially about a man trying to prove his nationality to his mother (read: country) and masculinity to his wife, who thinks hes a w**s. No wonder she calls him Wiz. That smashing transformation stretch during the interval block was testimony to that.

I have a theory; any film that employs amma sentiment as a strong emotional core will invariably be a blockbuster. Thats how Tamil cinema has conditioned the audience. In Velai Illa Pattathari, director Velraj milked this phenomenon to the films betterment. The pay off was huge and we got a satisfying, unpretentious masala movie. Dhanush plays Raghuvaran, channelling the inner aggression of an Angry Young Man reminiscent of Kamal Haasan in Sathya, another great masala movie about a man revolting against the system. Also, how refreshing was it to have the presence of a heroine, who for once, wasnt reduced to a must-have? Theres a quiet moment between Dhanush and Amala Paul that comes after the affecting Amma Amma song, that speaks volumes of how good writing elevates a simple scene. VIP had everything it its favour the amma sentiment, the comedy track from Vivekh, the shirtless-six-pack-show-off scene and the croon-able songs by Anirudh.

This sophomore film by Vijay Milton is a classic example of the rise of the underdog. But it is also about the survival of the fittest, in a quest to find an identity. Goli Soda tracks the lives of four boys who get their breaking point which, in turn, makes them undergo a transition from being boys to men. When you are stripped to bare bones, what do you do but rise above your oppressors? Yes, the action scenes towards the end are over the top, but Vijay Milton showed remarkable tenderness in the way he told their story.

When the director himself is a self-confessed fan of masala universe, youll get an irresistibly fun movie like Maari. A mischievous don with a bunch of sidekicks, who, actually, are funny for a change; a loosu ponnu who looks gorgeous and a thara local number from Anirudh...this is Balaji Mohan at his best, pumping (read: senjifying) every masala staple into the narrative. But, I would any day defend Maari 2 over Maari the latter had poor Vijay Yesudas screaming for attention. Of course, Maari 2 had Rowdy Baby aka Sai Pallavi, which made it all the more reason to sit up and join in the madness.

Writing a cop film in Tamil cinema means two things; a) its a shot of testosterone and b) elevating an actor to the position of a star. There is no middle ground. But Vijay Sethupathi brings a certain amount of vulnerability to his performance in Sethupathi, a refreshing masala movie by SU Arun Kumar that humanises the lives of police officers. That scene where Vijay Sethupathis son handles a revolver to evade bad guys is a brilliant mass scene. Rarely do you get to see a level-headed police officer in Tamil cinema. Sethupathi is one and hence the line: Kulirukkum neruppukum naduvula niruthuriyae.

A big-shot businessman masquerades under the identity of a beggar to fulfil a prophecy, in order to save his dying mother. How ridiculous is the premise, right? But Pichaikkaran showed us what it all it takes to convince the audience into its madness. Here too, theres amma sentiment, theres action and a case of the mistaken identity and above all, a filmmaker who understands our masala sensibilities. A whistle-worthy scene that comes to mind is where Arul (Vijay Antony) gets out of his car, adjusting his shades while showing the world his real identity.

Double-hero subjects are a ploy. You know the nicer twin will meet with his/her eventual death. In that sense, Kodi isnt any different. But RS Senthilkumar makes it up by writing a powerful female character, Rudhra (Trisha Krishnan). She is a powerful character NOT because she goes against a man, her lover. But because she was given a voice, more importantly an arc. Dhanush and Trisha were too good in their characters, especially when Rudhra leads Kodi to his own death.

If Thiagarajan Kumararaja gave an explanation as to what dharmam meant in Aaranya Kaandam, Pushkar-Gayatri took the tales of Vikram-Betal, exploring the concept of morality in Vikram Vedha, an ordinary but effective cat-and-mouse game that worked big time for its superb casting. As Vedha puts it simply, both Vikram and Vedha are cut from the same cloth and are a product of society. The narration presents two perspectives to the case of Good vs Evil, and makes the audience consider these two opposing views without taking sides the interrogation scene is a hoot! Not to mention Sam CS rollicking background score.

Looking from a broader perspective, the thing about masala is; if put together to proper use, it can fit into any movie. More than understanding the pulse of the audience, Pandiraj knows his audience. Kadaikutty Singam is a big, fat family drama that resonated with families across borders. Yes, it is bloated and clichd at the same time. But, who cares about all that when the movie turned out to be the biggest blockbuster of 2018?

A three-hour love letter written by a fan to the Superstar. Petta is an exploration of a masala sub-genre called Rajinikanth. Though it typically follows the Baashha formula to a large extent, the second half is where Karthik Subbaraj, the man who gave us the pulp gangster-drama Jigarthanda, takes control of the narrative where it plays out like a black comedy, when the whole Rama and Vali story sets in. From the gate-opening sequence in Apoorva Raagangal to the Raman Aandalum song from Mullum Malarum, everything about Petta felt meta. After a set of serious movies, Rajinikanth returned to familiar territory a path he created and mastered over the years, and it was absolute feast watching Rajini have fun. If anything, Petta is a cautionary reminder. That none of todays stars can ever come close to the enigma that is Rajini.

Baahubali and Sypder have been excluded from the list, given both films are bilingual.

Continued here:
Thuppakki to Petta: Tamil cinemas 15 best masala movies of the decade - The Hindu

Posted in Testosterone Shots | Comments Off on Thuppakki to Petta: Tamil cinemas 15 best masala movies of the decade – The Hindu

Novartis’s $90 million Swiss factory to help solve cell therapy bottleneck – Reuters

Posted: December 2, 2019 at 9:45 am

ZURICH (Reuters) - Swiss drugmaker Novartiss (NOVN.S) new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of its cell therapy Kymriah for cancer in 2020.

The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann

The new factory, expected to employ 450 people, will allow the drugmaker to make its Kymriah treatment for European patients without first having to fly their immune cells across the Atlantic Ocean.

The Swiss factory, as well as a separate French site also being expanded, are central to Novartiss plans to transform Kymriah from a modest $250 million-per-year seller into a $1 billion blockbuster as European demand rises.

We have already started to produce clinical batches at both sites and are on track to begin producing commercial product in 2020, Novartis said.

Basel-based Novartis sees cell and gene therapies eventually contributing about 15% of its revenue.[nL8N2874FU][nL5N25V4JJ]

T cells currently harvested from Europeans getting the $400,000-per-patient Kymriah blood cancer therapy must now be sent to a U.S. laboratory for re-engineering. Analysts have called the lack of manufacturing capacity a major bottleneck.

Novartis is investing some $500 million in new facilities around the world to address production bottlenecks and drug companies including Novartis, Pfizer (PFE.N) and others, have plans to spend $2 billion building out gene and cell therapy manufacturing after rapid expansion into these treatments.

Kymriahs global rollout in 20 countries, plus Novartiss efforts to expand the therapys indications, make adding commercial production a priority, including in China and Japan. [nL8N1WD64W]

Kymriahs 2018 approval was hailed as a breakthrough as a last-ditch treatment for acute lymphoblastic leukemia and diffuse large B-cell lymphoma. T-cells are extracted from patients, modified to attack their cancer, then re-infused in the hope they work where other treatments failed.

But its complex production, tailor-made for each patient, poses logistical challenges compared to off-the-shelf treatments, especially in Europe where Novartis lacked commercial manufacturing.

The key factor in bringing local manufacturing to each region is to make Kymriah available as quickly as possible, Novartis said.

(This story removes reference to Zolgensma, which will not be made at new Swiss factory in 2020.)

Reporting by John Miller; Editing by Elaine Hardcastle

Continued here:
Novartis's $90 million Swiss factory to help solve cell therapy bottleneck - Reuters

Posted in Cell Therapy | Comments Off on Novartis’s $90 million Swiss factory to help solve cell therapy bottleneck – Reuters

Vertex plans major Boston expansion to support gene, cell therapy ambitions – FiercePharma

Posted: December 2, 2019 at 9:45 am

Vertex Pharmaceuticals is preparing to grow even biggeranother 256,000 square feet bigger, to be exact.

The drugmaker is in advanced talks to lease a building in Innovation Square, a research campus in Bostons Raymond Flynn Marine Industrial Park, The Boston Globe reported.

The target is the entire second phase of the new R&D hub that developer Related Beal is building on the South Boston waterfront. Its close to Vertexs existing 1.1 million-square-feet Fan Pier headquarters and would serve as a research and manufacturing facility for gene and cell therapies, according to the newspaper.

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Vertex scoured the greater Boston region for a new foothold, including sites in Cambridge, Waltham and Watertown, but picked the Innovation Square because its one of the most advanced projects in the neighborhood, on track to open in 2021, Vertex CEO Jeffrey Leiden reportedly said.

Expansion at the Innovation Square comes as the biotech giant diversifies beyond its fundamental cystic fibrosis business and into the burgeoning gene and cell therapy arena.

The question became how are we going to grow those programs if were running out of space at Fan Pier? said Leiden, as quoted by the Globe. The answer is a new building.

Leiden is transitioning to executive chairman, handing the baton to Chief Medical Officer Reshma Kewalramani. But before he moves up, a blueprint for Vertexs future growth has been laid out.

RELATED:The top 10 best-paying places to work in biopharma | 7. Vertex Pharmaceuticals

In June, Vertex put down $245 million upfront to acquire Exonics and its gene editing technology, which uses CRISPR to repair dystrophin, the protein missing in patients with Duchenne muscular dystrophy (DMD). At the same time, it shelled out $175 million upfront to deepen its ties with CRISPR Therapeutics, also for using CRISPR-Cas9 to develop DMD and myotonic dystrophy Type 1 therapies.

The first project coming out of the CRISPR-Vertex partnership has just shown promise. CTX001, a CRISPR-based therapy for severe blood disorders marked by abnormal hemoglobin, helped a beta thalassemia patient live without transfusions for nine months, and a sickle cell patient was free of the painful vaso-occlusive crises after four months, the pair unveiled last week.

Vertex also agreed to pay $950 million to snatch up Semma Therapeutics and its stem cell treatment for Type 1 diabetes.

RELATED:Vertex, CRISPR's gene-editing treatment for blood disorders shows promise in early data

The new building Vertex plans to lease will house 300 to 400 people, including employees from Exonics and Semma, as well as new hires, Leiden said, according to the Globe. Besides the lab and office space at its Fan Pier HQ, Vertex also has a lease for about 100,000 square feet of space in the Marine Industrial Park for certain logistical and laboratory operations and manufacturing equipment, the companys annual securities filing shows.

On the companys third-quarter earnings call in October, Leiden said the company will continue to do deals on early-stage assets, especially bolt-on deals to furtherits gene editing strategy.

Meanwhile, the cystic fibrosis franchise will continue to provideVertexs revenue backbone for some time. Last month, the company wonFDA approval for Trikafta, a triple combo designed to treat cystic fibrosis patients with a mutated delF508 gene, which is found in 90% of the U.S. cystic fibrosis population.

The rest is here:
Vertex plans major Boston expansion to support gene, cell therapy ambitions - FiercePharma

Posted in Cell Therapy | Comments Off on Vertex plans major Boston expansion to support gene, cell therapy ambitions – FiercePharma

Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential – Cancer Network

Posted: December 2, 2019 at 9:45 am

A first-of-kind multi-antigen targeted off-the-shelf chimeric antigen receptor (CAR)-natural killer (NK) cell with engineered persistence has the potential to be a readily available treatment option for patients, Robert A. Brodsky, MD, said in a preview of the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.

As most of you are well aware, CAR T-cell (therapy has) captured the imagination of physician scientists and patients alike, mainly for their incredible efficacy in treating B-cell malignancies like acute lymphocytic leukemia and non-Hodgkin lymphomas, said Brodsky, who serves as secretary of ASH and is also the director of the division of hematology at Johns Hopkins Medicine.

However, he added, this treatment option does not come without its drawbacks: namely, time, expenses, toxicity.

Only about two-thirds of patients enrolled in CAR T-cell trials will actually see infusion because often the disease will progress during the time it takes to make a successful product, Brodsky said.

Therefore, there is a need to develop a more timely infusion that can be associated with lower costs, and hopefully, less toxicity.

At the upcoming ASH Annual Meeting & Exposition, being held from December 7-10 in Orlando, Florida, Jode P. Goodridge, PhD, will present on his teams proof-of-concept study of induced pluripotent stem cell (iPSC)-derived effector cells.

iPSC-derived effector cells offer distinct advantages for immune therapy over existing patient- or donor- derived platforms, both in terms of scalable manufacturing from a renewable starting cellular material and precision genetic engineering that is performed at the single-cell level, the researchers wrote in their abstract. iPSC derived natural killer (iNK) cells offer the further advantage of innate reactivity to stress ligands and MHC downregulation and the potential to recruit downstream adaptive responses.

The candidate, called FT596, is consistently manufactured from a master iPSC line engineered to uniformly express an NK cell-calibrated CD19-targeting CAR, an enhanced functioning high-affinity, non-cleavable CD16, and a recombinant fusion of IL-15 and IL-15 receptor alpha for cytokine-autonomous persistence, according to the abstract.

What the authors here did is take advantage of the use of induced pluripotent stem cells and differentiated them to natural killer cells. Natural killer cells are not T cells but they are another form of lymphocytes that can be very effective in killing cancer cells. What they did is they engineered these pluripotent stem cells to target B cells, and they are specifically targeting the CD19 antigen on B cells and showing that these are very effective in cell line models and animal models, explained Brodsky.

However, of note, this product has not been tested in humans yet.

The big advance here is that this offers the potential of having a readily available source of basically CAR-NK cells that wouldnt need time to grow them up before they would be infused, Brodsky concluded.

Goodridge JP, Mahmood S, Zhu H, et al. FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies. Presented at: 61st ASH Annual Meeting & Exposition Meeting preview; to be presented December 7, 2019; Orlando, Fla. Abstract 301.

See the original post:
Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential - Cancer Network

Posted in Cell Therapy | Comments Off on Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential – Cancer Network

Why Stem Cell Therapy Might Be Your Answer To Chronic Pain – Patch.com

Posted: December 2, 2019 at 9:45 am

This article is sponsored by The Art of Pain Management and Regenerative Medicine.

Having performed more than 25,000 procedures throughout the last decade, Dr. Jarrad Teller and Dr. Michael Schina of the Art of Pain Management (AOPM) are just getting started. Ten years ago, Dr. Teller, a chiropractor with degrees in physiotherapy and kinesiology, partnered with Dr. Schina, a vascular and trauma surgeon. Together, the pair has created one of the most successful interventional pain management practices in the tri-state area thanks to their multifaceted approach to patients. Modalities of treatment that are used by AOPM include yoga, meditation, vitamins and herbs, diet programs and spine and joint injections.

"Two years ago, our office began using stem cells to treat arthritic conditions. Previously, injections with cortisone and local anesthetic temporarily relieved a patient's pain. With stem cell injections, the patient's injury began to heal and osteoarthritis improved."

Stem cell therapy utilizes multi-potent cells that are capable of differentiating and growing into various types of tissue in the body. Stem cells act as beacon cells that find areas of inflammation (areas of need in the body) and reprogram the body's own stem cells to regenerate tissue. Stem cell function requires a healthy milieu. That is why blood analysis and correction of abnormalities prior to stem cell therapy is so important.

Osteoarthritis of the spine (neck and back), shoulder, knee, hip and ankle are the most common conditions that AOPM treats. Other conditions for which patients seek treatment include COPD, autoimmune disorders and spinal injuries, in addition to unexplained illnesses.

With traditional pain management that utilizes cortisone injections, yoga, meditation, lifestyle changes and diet, about half of patients fail to improve. This is largely related to the fact that cortisone treats only the patient's symptoms and does nothing to alleviate the underlying osteoarthritis. For the other half of patients, stem cell therapy offers the potential to improve the osteoarthritis by regenerating tissue and may be a viable option.

Art of Pain Management and Regenerative Medicine

3300 Grant Ave. Philadelphia, PA 19114

610-352-1710

Read more here:
Why Stem Cell Therapy Might Be Your Answer To Chronic Pain - Patch.com

Posted in Cell Therapy | Comments Off on Why Stem Cell Therapy Might Be Your Answer To Chronic Pain – Patch.com

Cell Therapy and Tissue Engineering Market Future Scope With Upcoming Opportunities 2025 (Betalin Therapeutics, BioCardia, Inc, BioReliance…

Posted: December 2, 2019 at 9:45 am

The market study report by reportsvale.com entitled Global Cell Therapy and Tissue Engineering Market Size, Status and Forecast 2019-2025 emphasizes on changing dynamics, growth-driving factors, restraints, and limitations. This allows understanding of the Global Seed Germination Trays market and benefits from any fruitful opportunities available in the report. It includes a detailed analysis of the Global Cell Therapy and Tissue Engineering in customer requirements, customer preferences, and the competitive landscape of the overall market. The study is divided into two segments i.e type and applications.

A FREE SAMPLE CAN BE REQUESTED HERE https://reportsvalue.com/report/global-cell-therapy-and-tissue-engineering-market-size-status-and-forecast-2019-2025/#Free-Sample-Report

The competition in the global Cell Therapy and Tissue Engineering Market is analyzed, taking into consideration price, revenue, sales, and market share by company, market concentration rate, competitive situations and trends, expansion, merger and acquisition, and market shares of top 5 and 10 companies.

The study includes the following key players in the Cell Therapy and Tissue Engineering market-

Detailed Segmentation of the market:

By Type-

By Application-

Based on regions, the market is expected to grow across various geographic regions, such as:-

A FULL REPORT CAN BE ACCESS FROM HERE https://reportsvalue.com/report/global-cell-therapy-and-tissue-engineering-market-size-status-and-forecast-2019-2025/

There are 13 chapters to present the Cell Therapy and Tissue Engineering Market.

Table of contents 1. Report Overview2. Global Growth Trends3. Market Share by Manufacturers4. Cell Therapy and Tissue Engineering Market Size by Type5. Cell Therapy and Tissue Engineering Market Size by Application6. Production by Regions7. Cell Therapy and Tissue Engineering Consumption by Regions8. Company Profiles9. Cell Therapy and Tissue Engineering Market Forecast10. Value Chain and Sales Channels Analysis11. Opportunities & Challenges, Threat and Affecting Factors12. Key Findings13. Appendix

Access full report with TOC https://reportsvalue.com/report/global-cell-therapy-and-tissue-engineering-market-size-status-and-forecast-2019-2025/#Table-Of-Contents

About ReportsValue Reportsvalue is developed to provide the best and most important research required to all commercials to all commercial, industries and profit-making ventures in any sectors of online business. We take pride in our ability to satisfy the market research needs of both domestics and international businesses. Reportsvalue has access to the worlds most comprehensive and up-to-date database in your business sectors, including countless market reports that can provide you with valuable data relating to your business we understood the need of our client, and keep our reports updated as market requirement changes.

Customize the study? Contact us at inquiry@reportsvalue.com to ensure you get a report that suits your needs.

Link:
Cell Therapy and Tissue Engineering Market Future Scope With Upcoming Opportunities 2025 (Betalin Therapeutics, BioCardia, Inc, BioReliance...

Posted in Cell Therapy | Comments Off on Cell Therapy and Tissue Engineering Market Future Scope With Upcoming Opportunities 2025 (Betalin Therapeutics, BioCardia, Inc, BioReliance…

Kite Energizes Marylands Cell Therapy and Biomanufacturing Community Around Mission to Cure Cancer – BioBuzz

Posted: December 2, 2019 at 9:45 am

In May of 2018 Kite Pharma, a Gilead Company, announced the opening of a new Neo Antigen Facility in Gaithersburg, MD. Less than one year later in April of 2019, the company, announced that it was building a new biomanufacturing facility on a 20-acre site in Frederick, MD. Since then, Kite has been diligently working to build a world-class leadership team at both sites to achieve an important mission.

Those leaders are now onboard and are out sharing their important mission by engaging the regional community to recruit and hire the talent they need to fill more than 360 job openings across Maryland..

This November, in one of its first regional community events, Kite sponsored a BioBuzz Meet and Greet networking event to get their message out to the local industry. A few dozen of Kites employees, including Chris McDonald, VP of Manufacturing and Frederick Site Head, and Wayne Hardy, Senior Director of Manufacturing and Site Head at Kites Neo Antigen Facility, shared the powerful, patient-focused why behind Kites mission.

Kite is pleased and happy to be part of this community. Were here to make a difference. Were on a mission to cure cancer, stated Hardy.

There are a lot of people out there who are suffering there is probably not a single person in this room untouched by cancer. Think about 10 years from now. You could be telling your kids or grandkids I was part of the solution to cure cancer. Thats why were here in this room right now, he added.

More than 125 people from across the BioHealth Capital Region (BHCR) gathered to hear Kites inspirational mission, learn first-hand about the company and get to personally meet its executives, hiring teams and staff.

At the event, McDonald shared that Kite had hired approximately 50 staff to date and anticipates bringing about 160 employees on board by the end of 2020 when the new facility is complete. McDonald understands that the talent market for cell therapy and biomanufacturing is highly competitive in the BHCR and sees regional collaborations and community engagement as important mechanisms to ensure Kite is able to develop and attract the right talent. The meet and greet event with BioBuzz is a good example of how Kite is accomplishing this.

In the end, the best thing you can do as an employer is to value your employees. At Kite, were totally focused on creating a workplace environment where our people are excited to come to work each and every day. Thats my aspiration for the Frederick facility, he added.

McDonalds philosophy appears to be one that extends throughout Kite as a company. BioSpace recently rated Kite in its Ideal Employer Report as one of the top 15 Biopharma Employers to provide opportunities for promotion.

Kites expansion in Maryland will provide many industry professionals with the opportunity to join a company that is a world leader in the rapidly emerging field of cell therapy. As the company grows in the coming years they expect much of their hiring to be focused around manufacturing, engineering, facilities, process development, and R&D positions.

Kites growth is built on the foundation of its industry-leading position in the cell therapy field. In late August 2017, Kite Pharma was acquired by Gilead Life Sciences for $12B. Shortly thereafter, the FDA approved Kites CAR-T cancer therapy, YESCARTA, making it one of the first autologous cell therapies ever approved by the FDA for cancer. The success of YESCARTAwhich is a treatment for non-hodgkins lymphomahas sparked significant growth at Kite, including the construction of its new 280,000 square foot advanced cell manufacturing facility that is set to open toward the end of 2020. The new facility will allow Kite to significantly expand its ability to manufacture next-generation oncology treatments, including YESCARTA and other investigational therapies.

YESCARTA is an amazing product thats really curing cancer. Making autologous cell therapies is labor-intensive and expensive, as we all know. Thats what makes our new facility so interesting: were implementing automation and innovation at the new facility to drive down costs and to make more reliable products for patients, stated McDonald.

McDonald also shared the news that Kite is currently preparing to present its ZUMA-1 trial 3-year survival data at the upcoming American Society of Hematology (ASH) Conference in December, which will mark a major milestone for the company that could lead to the possible treatment of other blood cancers beyond non-hodgkins lymphoma.

With this news on the horizon and the impending opening of its new facility, recruiting and hiring the right talent for its two Maryland facilities will prove critical to Kites continued overall success.

The collaborative, patient-first spirit driving Kite Pharmas mission to cure cancer was palpable at the BioBuzz event. McDonald and Hardys inspirational words, along with the hundreds of conversations with other Kite employees that night, made a memorable first impression on the audience and served as powerful signals that Kite Pharma will be an active and important player in the BHCR for years to come.

Though the event was only a few hours long, Kites powerful message is now resonating across the BHCR around water coolers, break rooms and kitchen tables as it gets shared by the attendees that experienced it.

For more on Kite, visit their career page.

Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.

More:
Kite Energizes Marylands Cell Therapy and Biomanufacturing Community Around Mission to Cure Cancer - BioBuzz

Posted in Cell Therapy | Comments Off on Kite Energizes Marylands Cell Therapy and Biomanufacturing Community Around Mission to Cure Cancer – BioBuzz

Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? – Kaiser Health News

Posted: December 2, 2019 at 9:45 am

A lack of a uniform policy allows convicted and accused perpetrators to access some dating apps and leaves users vulnerable to sexual assaults, according to an investigation. Public health news is on stem cell heart therapy, flu season, Parkinson's disease, poetry therapy, problems with blood-sugar monitors, warnings about ski helmets, a grateful transplant patient, children prone to violent outbursts, and more.

ProPublica:Tinder Lets Known Sex Offenders Use The App. Its Not The Only One.Susan Deveau saw Mark Papamechails online dating profile on PlentyofFish in late 2016. Scrolling through his pictures, she saw a 54-year-old man, balding and broad, dressed in a T-shirt. Papamechail lived near her home in a suburb of Boston and, like Deveau, was divorced. His dating app profile said he wanted to find someone to marry. Deveau had used dating websites for years, but she told her adult daughter the men she met were dorky. (Flynn, Cousins and Picciani, 12/2)

The Washington Post:Benefits Of Stem Cell Heart Therapy May Have Nothing To Do With Stem Cells, A Study On Mice SuggestsFor 15 years, scientists have put various stem cells into seriously ill patients hearts in hopes of regenerating injured muscle and boosting heart function. A new mouse study may finally debunk the idea behind the controversial procedure, showing the beneficial effects of two types of cell therapy are caused not by the rejuvenating properties of stem cells, but by the bodys wound-healing response which can also be triggered by injecting dead cells or a chemical into the heart. (Johnson, 11/27)

The Associated Press:Flu Season Takes Off Quickly In Deep South StatesThe flu season is off and running in the Deep South. The most recent weekly flu report from the Centers for Disease Control and Prevention finds high levels of flu-like illness in Alabama, Arkansas, Georgia, Nevada, South Carolina and Texas. The highest level in that report for the week ended Nov. 16 was in Mississippi. Doctors in the Magnolia State say theyre already seeing lots of patients. (11/29)

The New York Times:Swimmers Beware Of Deep Brain StimulationA lifelong swimmer leapt into deep water near his lakeside home, and was horrified to find himself completely unable to swim. Had his wife not rescued him, he might have drowned. He had recently received an electronic brain implant to control tremors and other symptoms of Parkinsons disease, and somehow the signals from the device had knocked out his ability to coordinate his arms and legs for swimming. (Grady, 11/27)

The Wall Street Journal:A Prescription Of Poetry To Help Patients Speak Their MindsDr. Joshua Hauser approached the bedside of his patient, treatment in hand. But it wasnt medicine he carried. It was a copy of a 19th-century poem titled Invictus. It isnt often that doctors do rounds with poetry. But Dr. Hauser, section chief of palliative care at the Jesse Brown VA Medical Center, and colleagues are testing it as part of a pilot study. He entered Mr. Askews room. The patient had asked for Invictus, a dark poem by William Ernest Henley that he remembered from his past. (Reddy, 12/1)

The Wall Street Journal:Diabetes Patients Blood-Sugar Data Arent Being SharedParents of young diabetes patients say they havent been getting crucial readings from blood-sugar monitors worn by their children since early Saturday. The technological breakdown, the origin of which isnt certain, threatens the proper care of the young diabetes patients. (Loftus, 12/1)

The New York Times:Study Warns Helmets Dont Offer Full Protection On SlopesCONCORD, N.H. For several years now, it has been almost de rigueur for skiers and snowboarders to strap on a helmet amid rising concerns about safety on the slopes. But a new study caution that helmets cannot protect skiers from all head injuries. (11/28)

Kaiser Health News:For Artist Inspired By Illness, Gratitude Outweighs PainPeople often ask Dylan Mortimer how it feels to breathe through transplanted lungs. He gets that a lot because while most people go through life with one pair of lungs, Mortimer is on his third. The 40-year-old artist has endured two double lung transplants in the past two years. He often shares his journey onstage as a speaker. But when the curtain closes, he leaves the rest of the storytelling to art. Im alive because of what someone else did, Mortimer said. That is humbling in all the best ways. (Anthony, 12/2)

NPR:Teens Who Threaten And Hit Their Parents: That's Domestic Violence TooNothing Jenn and Jason learned in parenting class prepared them for the challenges they've faced raising a child prone to violent outbursts. The couple are parents to two siblings whom they first fostered as toddlers and later adopted. In some ways, the family today seems like many others. Jenn and Jason's 12-year-old daughter is into pop star Taylor Swift and loves playing outside with her older brother. (Herman, 11/29)

NPR:Give Thanks For Adult Siblings And The Ties That BindWe didn't expect to need the card table for spillover seating at this year's Thanksgiving dinner. We would be fewer than usual, just nine altogether, and the littlest one's high chair needs no place setting. As we got things ready, I felt deep gratitude for the family members who would be here my husband, our two daughters, their husbands, my sister-in-law's 90-year-old mother and our two delightful granddaughters. But I also knew I would deeply miss the ones who couldn't make it. (Henig, 11/28)

The Washington Post:Doctors In China Found Tapeworms In Brain Of Man Who Ate Undercooked Meat In Hot PotA Chinese man sought medical attention for seizures and a headache that lasted nearly a month. Doctors found that tapeworms from undercooked meat were causing his pain. Researchers at the First Affiliated Hospital of Zhejiang University published a paper last week that details the plight of 46-year-old construction worker Zhu (an alias for the patient) in the eastern Zhejiang province of China who bought pork and mutton about a month ago for a spicy hot pot broth. (Beachum, 11/27)

See original here:
Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? - Kaiser Health News

Posted in Cell Therapy | Comments Off on Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? – Kaiser Health News

Stem cells may trigger immune repair to mend hearts – BioNews

Posted: December 2, 2019 at 9:45 am

2 December 2019

Stem cell therapies may become redundant in repairing cardiac function after a heart attack, suggests a new study in mice.

It showed how stem cell treatments can heal hearts by triggering an immune response which can be achieved by using a chemical instead.

'This work is paradigm-shifting because it demonstrates a mechanism to explain a perplexing phenomenon that has intrigued cardiologists as a result of decades of cardiac stem cell trials,' Dr Jonathan Epstein at the University of Pennsylvania's Perelman School of Medicine in Philadelphia told The Scientist.

Stem cell therapies to repair damaged heart tissue are currently being tested in human clinical trials. In these treatments, human stem cells are injected into the heart and this leads to an improvement in heart function. However, how this works is not fully understood.

One possibility is that the injected stem cells are incorporated into the heart tissue and repair the damage. However, the latest study, published in the journal Nature, suggests that this may not be the case. Instead, the study indicated that the repair is actually a result of triggering the innate immune response.

Researchers injected different types of stem cell or a chemical inducer (zymosan) of the innate immune response into an experimental mouse model of heart disease. They saw improvement in heart function that was similar in all cases, and showed that this repair occurs via activation of macrophage cells of the innate immune system.

'The innate immune response acutely altered cellular activity around the injured area of the heart so that it healed with a more optimised scar and improved contractile properties,' said Dr Jeffery Molkentin at the University of Cincinnati and Cincinnati Children's Hospital Medical Centre, Ohio, who led the study. 'The implications of our study are very straightforward and present important new evidence about an unsettled debate in the field of cardiovascular medicine.'

The work could open up new possibilities for optimising the treatments currently in development, as well as alternative new therapies.

'If there is a chemical off-the-shelf, it would be a much more feasible therapy [than stem cell transplants],'Dr Kory Lavine at Washington University in St Louis, Missouri, told Nature News.

Read more:
Stem cells may trigger immune repair to mend hearts - BioNews

Posted in Cell Therapy | Comments Off on Stem cells may trigger immune repair to mend hearts – BioNews

Page 1,248«..1020..1,2471,2481,2491,250..1,2601,270..»